Astellas Pharma Inc.
ALPMF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | $535,480 | $68,422,000 | $74,896,000 | -$97,660,000 |
| Dep. & Amort. | $319,707 | $47,804,000 | $47,683,000 | $51,164,000 |
| Deferred Tax | $0 | $0 | $0 | $0 |
| Stock-Based Comp. | $0 | $0 | $0 | $0 |
| Change in WC | $586,119 | -$47,168,000 | -$22,465,000 | -$72,155,000 |
| Other Non-Cash | $110,053 | -$68,670,443 | $961,000 | $134,677,000 |
| Operating Cash Flow | $1,551,359 | $54,837,000 | $101,075,000 | $16,026,000 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$224,290 | -$12,808,000 | -$9,699,000 | $2,294,000 |
| Net Acquisitions | $0 | $0 | $0 | $0 |
| Inv. Purchases | $0 | $0 | $0 | $0 |
| Inv. Sales/Matur. | $0 | $0 | $0 | $0 |
| Other Inv. Act. | $121,646 | $12,684,763 | $6,734,000 | -$33,016,000 |
| Investing Cash Flow | -$102,644 | -$123,237 | -$2,965,000 | -$30,722,000 |
| Financing Activities | – | – | – | – |
| Debt Repay. | -$1,013,851 | -$10,386,000 | -$23,547,000 | -$15,568,000 |
| Stock Issued | $0 | $0 | $0 | $0 |
| Stock Repurch. | -$7 | -$727,000 | -$1,000 | -$1,000 |
| Dividends Paid | $0 | -$66,241,000 | $0 | -$66,234,000 |
| Other Fin. Act. | $35,375 | $77,277,380 | -$67,264,000 | -$22,493,000 |
| Financing Cash Flow | -$978,483 | -$76,620 | -$90,812,000 | -$104,296,000 |
| Forex Effect | -$24,401 | $51,266 | $1,209,000 | $5,865,000 |
| Net Chg. in Cash | $445,831 | $215,399,000 | $8,507,000 | $179,865,000 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $1,494,654 | $0 | $179,865,000 | $0 |
| End Cash | $1,940,485 | $215,399,000 | $188,372,000 | $179,865,000 |
| Free Cash Flow | $1,460,532 | $42,029,000 | $91,376,000 | $18,320,000 |